Stockscreener 앱 받기
1.44
6.67%
0.09
시간 외 거래:
1.49
0.05
+3.47%
전일 마감가:
$1.35
열려 있는:
$1.37
하루 거래량:
297.51K
Relative Volume:
0.63
시가총액:
$47.65M
수익:
-
순이익/손실:
$-37.65M
주가수익비율:
-1.0213
EPS:
-1.41
순현금흐름:
$-24.14M
1주 성능:
+16.13%
1개월 성능:
+28.57%
6개월 성능:
-61.90%
1년 성능:
-70.49%
1일 변동 폭
$1.33
$1.44
1주일 범위
$1.20
$1.45
52주 변동 폭
$0.60
$6.80
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
명칭
Reviva Pharmaceuticals Holdings Inc
전화
(408) 501-8881
주소
10080 N WOLFE ROAD, CUPERTINO
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-01-24 | 개시 | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc 주식(RVPH)의 최신 뉴스
Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference - The Manila Times
Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference - GlobeNewswire
Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference - StockTitan
CA Pharma Co. Reports Positive Phase 3 Data for Schizophrenia Treatment - Streetwise Reports
EF Hutton Initiates Coverage of Reviva Pharmaceuticals Holdings (RVPH) with Buy Recommendation - MSN
RVPH’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Market Momentum: Reviva Pharmaceuticals Holdings Inc. (RVPH) Registers a 9.40 Increase, Closing at 1.28 - The Dwinnex
RVPH: RECOVER Biomarker KOL Event - Yahoo Finance
Closing Strong: Reviva Pharmaceuticals Holdings Inc. (RVPH) Ends at 1.12, Down -13.85 from Last Close - The Dwinnex
A stock that deserves closer examination: Reviva Pharmaceuticals Holdings Inc. (RVPH) - US Post News
Reviva reports positive schizophrenia trial results - Investing.com India
Reviva reports positive schizophrenia trial results - Investing.com
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia - GlobeNewswire
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia - StockTitan
How to interpret Reviva Pharmaceuticals Holdings Inc. (RVPH)’s stock chart patterns - US Post News
Reviva Pharmaceuticals Holdings Inc. (RVPH) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
RVPH’s Stock Market Adventure: -79.42% YTD Growth Amidst Volatility - The InvestChronicle
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker - GlobeNewswire
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024 - StockTitan
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024 - Yahoo Finance
RVPH: August OLE Update - Yahoo Finance
Reviva Pharmaceuticals Launches Multi-Million Share Offering - TipRanks
Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) Drops -25.71% In Early Trade; What Lies Ahead? - Stocks Register
Reviva Pharmaceuticals Holdings Inc. [RVPH] stock Initiated by ROTH MKM analyst, price target now $12 - The DBT News
Check Out Reviva Pharmaceuticals Holdings Inc. (RVPH)’s Trade Data Rather Than the Analysts’ Views - SETE News
Reviva Pharmaceuticals Announces Pricing of $5.0 Million - GlobeNewswire
Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules - Marketscreener.com
Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules - StockTitan
A closer look at Reviva Pharmaceuticals Holdings Inc. (RVPH) is warranted - US Post News
Reviva Pharmaceuticals Holdings Inc.’s Shares Reel: -62.34% Quarterly Revenue Decline Amid 19.20M Market Cap - The InvestChronicle
Ratios Reveal: Breaking Down Reviva Pharmaceuticals Holdings Inc. (RVPH)’s Financial Health - The Dwinnex
Vanguard Group Inc. Purchases 26,854 Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Rating Reaffirmed by Maxim Group - Defense World
Maxim Group Downgrades Reviva Pharmaceuticals Holdings (RVPH) - MSN
Reviva Pharmaceuticals Holdings Inc. Inc. (RVPH) Price Performance Over the Years: A Comparative Study - The InvestChronicle
Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights - StockTitan
Balance Sheet Insights: Reviva Pharmaceuticals Holdings Inc. (RVPH)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
RVPH stock touches 52-week low at $0.76 amid market challenges - Investing.com
RVPH stock touches 52-week low at $0.76 amid market challenges - Investing.com Canada
RVPH stock touches 52-week low at $0.76 amid market challenges - Investing.com UK
Market Momentum: Reviva Pharmaceuticals Holdings Inc. (RVPH) Registers a -4.80 Decrease, Closing at 0.90 - The Dwinnex
Reviva secures US patent for lung disease treatment By Investing.com - Investing.com Canada
Reviva secures US patent for lung disease treatment - Investing.com
Reviva Announces Grant of U.S. Patent Covering Use of - GlobeNewswire
Reviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis - Yahoo Finance
Reviva secures US patent for lung disease treatment - Investing.com India
RVPH Stock Plummets to 52-Week Low at $0.94 Amid Market Struggles - Investing.com
Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price Down 8.5% - Defense World
Reviva Pharmaceuticals Holdings Inc (RVPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
4.86%
자본화:
|
볼륨(24시간):